Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

2526-026-STA-WBS Provision of Altuvoct (Efanesoctocog alfa) recombinant FVII

Velindre University NHS Trust

This public procurement record has 2 releases in its history.

Award

14 Oct 2026 at 11:29

UK6 - Contract Award Notice
Award

30 Sep 2026 at 09:45

UK5 - Transparency Notice
Summary of the contracting process

Velindre University NHS Trust procured Altuvoct (efanesoctocog alfa), a recombinant factor VIII medicine for treating bleeding disorders. The requirement is for the medicine itself, rather than related clinical services or works. The Trust’s stated purpose was to provide Welsh patients with access to this NICE-approved medicine while a contract was being negotiated between the supplier and NHS England. The medicine was not available for procurement through the NHS England Bleeding Disorders Framework. The procurement is categorised as pharmaceutical products. The recorded delivery location is the United Kingdom; the Trust is based in Cardiff, Wales.

The procurement is complete and the Trust selected Swedish Orphan Biovitrum (SOBI) through a direct award. The stated rationale was that SOBI was the sole supplier of the required medicine and that purchase was critical for patient treatment. The award value is £270,000 excluding VAT, or £324,000 including VAT. The contract period runs from 27 October 2026 to 17 August 2028. The notice records one lot, covering the Altuvoct supply. The award is shown as pending. No separate evaluation criteria are recorded; the selection rationale is sole-supplier status and the critical need to treat patients.

This award shows demand from Velindre University NHS Trust for a NICE-approved treatment for bleeding disorders, in a context where the medicine was not available through the NHS England framework. A credible supplier for a similar requirement would need to supply the specific medicine and demonstrate that it can meet a critical patient-treatment need. The direct award was justified on the basis that the selected company was the sole supplier of the required medicine, so competing suppliers would need to offer the same required product to be relevant. This is a specialist pharmaceutical supply requirement, rather than a broad medicines catalogue or general healthcare services opportunity.

How relevant is this notice?

Notice Information

Notice Title

2526-026-STA-WBS Provision of Altuvoct (Efanesoctocog alfa) recombinant FVII

Notice Description

This note formally records that the Transparency Notice was not published at the required stage of the process, due to a procedural oversight. Once identified, the issue was promptly escalated and corrective action was taken to ensure a notice is completed and published in line with the relevant regulatory and governance requirements. Internal processes and controls have since been reviewed to reduce the risk of this happening again. This medicine is a NICE approved product which is not currently available for procurement under the Bleeding Disorders Framework, managed by NHS England. In order for Welsh patients to obtain access to this medicine while a contract is being negotiated between the supplier and NHS England, this contract is being direct awarded to SOBI.

Procurement Information

Sole supplier of the medicines required and purchase is critical for patient treatment.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-077d18
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/096904-2026
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
UK6 - Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Direct
Procurement Method Details
Direct award
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
£270,000 £100K-£500K
Contracts Value
Not specified

Notice Dates

Publication Date
14 Oct 2026Yesterday
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
14 Oct 2026Yesterday
Contract Period
27 Oct 2026 - 17 Aug 2028 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Pending
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
Velindre University NHS Trust
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
CARDIFF
Postcode
CF15 7QZ
Postcode Area
Cardiff
Country
Wales
Major Region (ITL 1)
TLL Wales
Basic Region (ITL 2)
TLL5 South East Wales
Small Region (ITL 3)
TLL51 Central Valleys and Bridgend
Delivery Location
Not specified
Local Authority
Rhondda Cynon Taf
Electoral Ward
Taff's Well
Westminster Constituency
Cardiff North

Supplier Information

Number of Suppliers
1
Supplier Name

Swedish Orphan Biovitrum (SOBI)

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...